Mechanisms of resistance to BCR–ABL TKIs and the therapeutic strategies: A review
Introduction
A reciprocal translocation between chromosomes 9 and 22 produces a Philadelphia chromosome which leads to the formation of the novel BCR–ABL fusion gene [1]. BCR–ABL is an active constitutive tyrosine kinase that activates multiple downstream signaling pathways resulting in the survival and proliferation of CML cells [2], [3] and leading to the myeloproliferation disorder of CML.
As the elaborate mechanisms of BCR–ABL are illustrated, several TKIs targeting at BCR–ABL have been synthesized and screened, and the introduction of these variety kinds of inhibitors have basically promoted the treatment of CML. There are many other BCR–ABL inhibitors, which have already been either applied in the clinical treatment with significant effects in certain malignancies or in the clinical trial, representing a revolutionary approach to cancer therapy.
Section snippets
Clinical importance of TKIs resistance
Majority of patients can expect normal life as long as they continually abide by BCR–ABL-inhibitor treatment, unfortunately, a multitude of patients develop TKI-resistance overtime. From this and other frontline clinical trials it is estimated that 20–30% of patients will develop either primary (failure to achieve a predetermined milestones) or secondary (loss of the response after initial achievement of predetermined milestones) TKIs resistance and do not respond optimally to TKIs therapy,
BCR–ABL and its signal transduction
In 1960, the Philadelphia chromosome was first described in cell cultures from CML patients. The BCR–ABL fusion gene leads to the production of an abnormal tyrosine kinase protein, resulting in the dysregulated downstream signaling pathways and the increased proliferation and survival of leukemic cells. First, the ABL-moiety kinase domain becomes very active in catalytic and phosphorylates a variety of different substrate proteins. Second, the BCR-moiety of the fusion contributes pivotal
BCR–ABL inhibitors
Up to now, there are three generation BCR–ABL inhibitors approved by FDA. Here is the elaborated common information of the BCR–ABL inhibitors in Table 1.
BCR–ABL inhibitor resistance mechnisms
By far, many TKIs-resistance mechanisms has been discovered which can be divided into two part, BCR–ABL-dependent and—independent mechanisms. BCR–ABL-dependent mechanisms include mutations and amplification of BCR–ABL, impaired signaling pathways; BCR–ABL independent mechanisms include drug efflux mediated ABC-transporters, micro environment which facilitate resistance and deficient BER (base excision repair) for choromosomal abnormalities (Fig. 2). Understanding the underlying causes of
Reversal strategies for BCR–ABL inhibitor resistance
Since resistance mechanisms have been elaborated in several ways, reversal strategies targeting at those mechanisms show a promising prospect. Importantly, some novel strategies of overcoming the resistance were developed and used in clinic. In addition, combination treatment also exhibit a longterm effect for BCR–ABL -inhibitor-resistant. Strategies for overcoming resistance of BCR–ABL inhibitors have been listed in Table 2.
Conclusion
Despite the clinical efficacy of the first-, second- and third-generation BCR–ABL inhibitors, many major problems persist: the long-term tolerability, the side effect induced by the inhibitors, the resistance to the inhibitors, the inability to eradicate CML stem cells and minimal residual disease. Fortunately, resistant mechanisms are illustrated in several ways and novel agents with theoretical good tolerability targeting multiple signaling pathways have been designed to sensitize cancer
Conflict of interest statement
The authors report no conflict of interest.
Reviewers
Professor Jin-ming Yang, MD, PhD: Dept of Pharmacology and the Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine500 University Drive, Hershey, PA 17033, USA.
Professor Xiang-Xi Mike Xu, PhD: School of Medicine, University of Miami, Miami FL 33136, USA.
Professor Jakob R Passweg, MD, MS: Hematology Division, Basel University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland.
Li-wu Fu MD, Ph.D., professor and director of Department of Experimental Research, Cancer Center, Sun Yat-sen University. He finished his Ph.D. program from Cancer Center, Sun Yat-sen University in 1996. And then he became a postdoctor in Medical University of South Carolina. He became a full professor in Cancer Center, Sun Yat-sen University in 2002. His major is Cancer Pharmacology. His active research field is cancer cell resistance and strategy.
References (181)
- et al.
Critical role for Gab2 in transformation by BCR/ABL
Cancer Cell
(2002) - et al.
Imatinib: a selective tyrosine kinase inhibitor
Eur J Cancer
(2002) - et al.
XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells
Leuk Res
(2013) - et al.
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cell by chemotherapeutic agents
Blood
(2013) - et al.
Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells
J Surg Res
(2013) - et al.
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia
Lung Cancer
(2013) - et al.
Dasatinib inhibits DNA repair after radiotherapy specifically in pSFK-expressing tumor areas in head and neck xenograft tumors
Transl Oncol
(2013) - et al.
Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action
Biochem Pharmacol
(2011) - et al.
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Blood
(2006) - et al.
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Blood
(2007)
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR–ABL mutations
Blood
Characterization of AMN107, a selective inhibitor of native and mutant Bcr–Abl
Cancer Cell
Nilotinib: a novel, selective tyrosine kinase inhibitor
Semin Oncol
Bcr–Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the AN kinase inhibitor nilotinib (AMN107)
Blood
Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases
Biochim Biophys Acta
Nilotinib-associated vascular events
Clin Lymphoma Myeloma Leuk
Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells
Biochem Biophys Res Commun
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Blood
Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia
Eur J Cancer
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Blood
The biology of CML blast crisis
Blood
Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Cancer Cell
BCR–ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
Blood
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients
Cancer Lett
Functional consequence of MDR1 expression on imatinib intracellular concentrations
Blood
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1
Biochim Biophys Acta (BBA)
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
Blood
A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
Molecular and cellular bases of chronic myeloid leukemia
Protein Cell
Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?
Expert Opin Pharmacother
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Nat Rev Cancer
Structure of the Bcr–Abl oncoprotein oligomerization domain
Nat Struct Biol
Structure, regulation, signaling, and targeting of abl kinases in cancer
Genes Cancer
BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia
Cancer Res
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr–Abl signal transduction and oncogenesis
Oncogene
Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)
Arch Pharm (Weinheim)
Acute leukaemia in bcr/abl transgenic mice
Nature
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
J Pharmacol Exp Ther
Platelet-derived growth factor β receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling
Proc Natl Acad Sci USA
Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors
Cancer Res
Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia
N Engl J Med
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
Cancer Res
Adherence to imatinib therapy in patients with gastrointestinal stromal tumors
Cancer Treat Rev
Imatinib as a novel therapeutic approach for fibrotic disorders
Rheumatology
Indications for imatinib mesylate therapy and clinical management
Oncologist
Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification
Science
Roots of clinical resistance to STI-571 cancer therapy
Science
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients
Clin Cancer Res
Dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias
N Engl J Med
Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance
Science
Cited by (82)
Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective
2024, Critical Reviews in Oncology/HematologyInterplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models
2024, Computers in Biology and MedicineA novel microscale platform for leukemia tumor treating field therapy and electrochemical screening
2022, Microelectronic EngineeringCitation Excerpt :TKIs caused significant improvement in remission, preventing disease progression and prolonging CML patients' survival. However, limitations of TKI treatment, such as resistance against the drug and adverse effects, have been frequently reported [4,5]. Accordingly, it is desired to find more efficient methodical approaches for overcoming TKI resistance, dose modifications of TKIs to reduce side effects and maintain efficacy [6,7].
A facile synthesis of a novel family of heterotricyclic hybrids: Spiro-pyrrolopyridazines
2022, Synthetic CommunicationsThe importance of personalized medicine in chronic myeloid leukemia management: a narrative review
2023, Egyptian Journal of Medical Human Genetics
Li-wu Fu MD, Ph.D., professor and director of Department of Experimental Research, Cancer Center, Sun Yat-sen University. He finished his Ph.D. program from Cancer Center, Sun Yat-sen University in 1996. And then he became a postdoctor in Medical University of South Carolina. He became a full professor in Cancer Center, Sun Yat-sen University in 2002. His major is Cancer Pharmacology. His active research field is cancer cell resistance and strategy.
Ke Yang Ph.D. candidate. Her research dissertation field is leukemia resistance.